Interestingly, the exploratory analyses found that median OS was longer in the atezolizumab plus chemotherapy arm versus the bevacizumab plus chemotherapy arm (23.3 vs. 11.2 mo, HR = 0.59, 95% CI: 0.39–0.90) in the SP263-defined PD-L1-high subgroup (PD-L1 expressing tumor cells ≥ 50%). The gene discussed is CD274; the disease is neoplasm.